Neuro-cells Market Summary

Key Factors Driving Neuro-cells Growth

1. Addresses a major unmet need in traumatic spinal cord injury

Neuro-Cells® is being developed for acute TSCI, a condition with no approved regenerative pharmacotherapy in Europe or the United States. Neuroplast estimates that approximately 29,000 patients annually across Europe and the U.S. sustain acute TSCI, while the associated socioeconomic burden exceeds €11.4 billion (approximately US$13 billion) per year. The absence of disease-modifying therapies creates a favorable commercial opportunity if Neuro-Cells® demonstrates clinically meaningful neurological recovery.

2. Positive clinical safety profile and advancement into Phase II/III development

Neuro-Cells® is an autologous bone marrow-derived hematopoietic and mesenchymal stem cell therapy administered intrathecally during the acute phase after injury to reduce secondary inflammatory damage and preserve neurological function. In the completed Phase I study (10 patients), the therapy demonstrated an excellent safety and tolerability profile with no product-related serious adverse events, supporting advancement into a randomized, placebo-controlled combined Phase II/III clinical program. In September 2023, Neuroplast completed enrollment of 16 patients in the multicenter Phase II study, representing an important de-risking milestone for future commercialization.

3. Potential expansion into multiple neurodegenerative diseases

Beyond TSCI, Neuroplast is exploring Neuro-Cells® for frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, and traumatic brain injury (TBI). Since these disorders share inflammatory and neurodegenerative mechanisms, successful proof-of-concept in SCI could substantially expand the addressable market while leveraging the same manufacturing platform. This pipeline expansion significantly enhances the long-term value proposition beyond a single indication.

4. Strong financial backing and accelerated development strategy

Neuroplast raised €10 million (approximately US$11.5 million) in Series B financing to support clinical development and pursue conditional EMA market approval. The company also received approvals from Spanish and Danish regulators to conduct a combined Phase II/III study, shortening the potential path to commercialization compared with traditional sequential development programs. These milestones improve investor confidence and reduce execution risk.

5. Commercial outlook and sales potential

Neuroplast has not released official sales forecasts or revenue guidance for Neuro-Cells®, and there are no verified analyst consensus sales estimates available from company filings or regulatory sources. Therefore, assigning specific revenue projections would be speculative. However, if ongoing Phase II/III studies confirm efficacy and lead to conditional EMA approval, Neuro-Cells® could benefit from first-mover advantage in the European regenerative medicine market for TSCI, with further upside from label expansion into additional neurodegenerative indications.

Neuro-cells Recent Developments

In November 2021, Dutch clinical phase biotech company Neuroplast and Hospital Nacional de Parapléjicos de Toledo in Spain, announced positive clinical Phase I results after analysis of ten patients suffering from Traumatic Spinal Cord Injury (TSCI). Data demonstrate that Neuroplast's investigational stem cell treatment Neuro-Cells appears to be safe and well tolerated, without product-related adverse events. The transformative treatment uses the patient's own stem cells to prevent (further) loss of function after sustaining TSCI, to potentially limit loss of mobility and independence of otherwise life-long impairment.

“Neuro-cells Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Neuro-cells for potential indication like Spinal cord injuries, Amyotrophic lateral sclerosis, Frontotemporal dementia, and Traumatic brain injuries in the 7MM. A detailed picture of Neuro-cells’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Neuro-cells for potential indications. The Neuro-cells market report provides insights about Neuro-cells’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Neuro-cells performance, future market assessments inclusive of the Neuro-cells market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Neuro-cells sales forecasts, along with factors driving its market.

Neuro-cells Drug Summary

Neuro-cells is an investigational autologous bone marrow-derived stem cell therapy being developed by Neuroplast for the treatment of traumatic spinal cord injury and other neurodegenerative disorders. The therapy consists of a patient's own bone marrow-derived cells that are processed to enrich regenerative and immunomodulatory cell populations before being administered intrathecally into the cerebrospinal fluid. Neuro-Cells is designed to reduce neuroinflammation, protect surviving neurons, promote tissue repair, and enhance functional recovery through the secretion of anti-inflammatory cytokines, growth factors, and other bioactive molecules rather than direct neuronal replacement. Early-phase clinical studies have demonstrated a favorable safety profile and encouraging signals of neurological improvement, supporting continued clinical development. The therapy has received orphan drug designation from both the U.S. Food and Drug Administration and the European Commission for traumatic spinal cord injury, underscoring its potential to address a significant unmet medical need in a condition with few effective restorative treatment options. The report provides Neuro-cells’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Neuro-cells Market Report

The report provides insights into:

• A comprehensive product overview including the Neuro-cells MoA, description, dosage and administration, research and development activities in potential indication like Spinal cord injuries, Amyotrophic lateral sclerosis, Frontotemporal dementia, and Traumatic brain injuries.
• Elaborated details on Neuro-cells regulatory milestones and other development activities have been provided in Neuro-cells market report.
• The report also highlights Neuro-cells‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The Neuro-cells market report also covers the patents information, generic entry and impact on cost cut.
• The Neuro-cells market report contains current and forecasted Neuro-cells sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Neuro-cells market report also features the SWOT analysis with analyst views for Neuro-cells in potential indications.

Methodology

The Neuro-cells market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Neuro-cells Analytical Perspective by DelveInsight

• In-depth Neuro-cells Market Assessment

This Neuro-cells sales market forecast report provides a detailed market assessment of Neuro-cells for potential indication like Spinal cord injuries, Amyotrophic lateral sclerosis, Frontotemporal dementia, and Traumatic brain injuries in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Neuro-cells sales data uptil 2034.

• Neuro-cells Clinical Assessment

The Neuro-cells market report provides the clinical trials information of Neuro-cells for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Neuro-cells Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Neuro-cells Market Potential & Revenue Forecast

• Projected market size for the Neuro-cells and its key indications
• Estimated Neuro-cells sales potential (Neuro-cells peak sales forecasts)
• Neuro-cells Pricing strategies and reimbursement landscape

Neuro-cells Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Neuro-cells Market positioning compared to existing treatments
• Neuro-cells Strengths & weaknesses relative to competitors

Neuro-cells Regulatory & Commercial Milestones

• Neuro-cells Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Neuro-cells Clinical Differentiation

• Neuro-cells Efficacy & safety advantages over existing drugs
• Neuro-cells Unique selling points

Neuro-cells Market Report Highlights

• In the coming years, the Neuro-cells market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Neuro-cells companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Neuro-cells’s dominance.
• Other emerging products for Spinal cord injuries, Amyotrophic lateral sclerosis, Frontotemporal dementia, and Traumatic brain injuries are expected to give tough market competition to Neuro-cells and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Neuro-cells in potential indications.
• Analyse Neuro-cells cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Neuro-cells sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Neuro-cells in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of Neuro-cells? How strong is Neuro-cells’s clinical and commercial performance?
• What is Neuro-cells’s clinical trial status in each individual indications such as Spinal cord injuries, Amyotrophic lateral sclerosis, Frontotemporal dementia, and Traumatic brain injuries and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Neuro-cells Manufacturers?
• What are the key designations that have been granted to Neuro-cells for potential indications? How are they going to impact Neuro-cells’s penetration in various geographies?
• What is the current and forecasted Neuro-cells market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Neuro-cells in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Neuro-cells for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is Neuro-cells? What is the duration of therapy and what are the geographical variations in cost per patient?